Cardiovascular, Renal and Metabolism (CVRM)皇冠官网网站

皇冠注册官网地址

皇冠注册官网地址

Shared risk factors of CVRM diseases are still often not diagnosed or addressed, 1-4皇冠注册官网地址


Up to 20 million 皇冠注册官网地址

people die from CVRM diseases each year, making them the leading causes of death across the globe5,6

Up to 94% 皇冠注册官网地址

of people with type-2 diabetes in the US have at least one other cardiovascular, renal or metabolic condition7

皇冠注册官网地址

of patients with heart failure also have chronic kidney disease8

Up to 40%皇冠注册官网地址

of patients hospitalised for heart failure have diabetes9


皇冠官网网站

皇冠官网网站


皇冠官网网站


Atacand, Atacand HCT, Atacand Plus皇冠官网网站

candesartan cilexetil

Brilinta/Brilique皇冠官网网站

ticagrelor

Bydureon皇冠官网网站

exenatide

Byetta皇冠官网网站

exenatide injection

Crestor皇冠官网网站

rosuvastatin

Farxiga/Forxiga皇冠官网网站

dapagliflozin

Komboglyze皇冠官网网站

saxagliptin and metformin HCl

Kombiglyze XR皇冠官网网站

saxagliptin and metformin XR

Lokelma皇冠官网网站

Sodium zirconium cyclosilicate

Onglyza皇冠官网网站

saxagliptin

Plendil, Modip, Splendil, Munobal, Flodil 皇冠官网网站

felodipine

Qtern皇冠官网网站

dapagliflozin and saxagliptin

Seloken ZOK, Toprol-XL, Betaloc ZOK皇冠官网网站

metoprolol succinate

Symlin皇冠官网网站

pramlintide acetate

Tenormin, Tenormine, Prenormine, Atenol 皇冠官网网站

atenolol

XIGDUO皇冠官网网站

dapagliflozin and metformin HCI

XIGDUO XR 皇冠官网网站

dapagliflozin and metformin HCI extended-release

Zestril皇冠官网网站

lisinopril dihydrate


皇冠官网网站


皇冠官网网站

皇冠官网网站

皇冠官网网站


We follow the science to develop innovative treatments and ultimately, modify or even halt the natural course of the disease and regenerate organs. We are agnostic to drug modality, we identify and validate novel targets based on genetics and human target validation and then apply the best modality to modulate the target. Together with key experts throughout the world we collaborate to accelerate our scientific progress, and to further define patient populations that may benefit from the novel cardio-renal-metabolic therapies we are developing.

Regina Fritsche-Danielson SVP, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D

New modalities皇冠注册官网地址


New technologies皇冠注册官网地址


New biology皇冠注册官网地址


Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).

 

皇冠注册官网地址

Phase I

皇冠官网网站

  • AZD2373 nephropathy
  • AZD2693 NASH
  • AZD6615 CV disease
  • AZD8233 CV disease
  • AZD9977 CV disease
  • MEDI6570 cardiovascular disease
  • MEDI7219 type-2 diabetes

Phase II

皇冠官网网站

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease
  • AZD8601 cardiovascular disease
  • cotadutide type-2 diabetes, obesity and NASH
  • MEDI3506 diabetic kidney disease
  • MEDI5884 cardiovascular disease
  • MEDI6012 cardiovascular disease
  • verinurad chronic kidney disease

Phase III

皇冠官网网站

  • Epanova severe hypertriglyceridaemia
  • Lokelma hyperkalaemia
  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end-stage renal disease

LCM Projects

皇冠官网网站

  • Brilinta/Brilique THALES acute ischaemic stroke or transient ischaemic attack
  • Brilinta/Brilique HESTIA prevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/Brilique THEMIS cardiovascular outcomes trial in patients with coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke
  • Bydureon BCise (autoinjector) type-2 diabetes
  • Farxiga/Forxiga Dapa-CKD renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga Dapa-HF worsening heart failure or cardiovascular death in patients with chronic heart failure (HFrEF)
  • Farxiga/Forxiga DECLARE- TIMI 58 cardiovascular outcomes trial in patients with type-2 diabetes
  • Farxiga/Forxiga DELIVER worsening HF or CV death in patients with chronic heart failure (HFpEF)
  • Farxiga/Forxiga DEPICT type-1 diabetes
  • Farxiga/Forxiga DETERMINE-Preserved heart failure with preserved ejection fraction (HFpEF)
  • Farxiga/Forxiga DETERMINE-Reduced heart failure with reduced ejection fraction (HFrEF)
  • Qternmet XR/Qtrilmet (saxagliptin/dapagliflozin metformin) type-2 diabetes
  • roxadustat anaemia in myelodysplastic syndrome
  • roxadustat chemotherapy induced anaemia
  • Xigduo XR/Xigduo type-2 diabetes


皇冠官网网站


皇冠官网网站


皇冠官网网站

 


皇冠官网网站


References

1.      Bjornstad et al. Curr Opin Endocrinol Diabetes Obes. 2014 August ; 21(4): 279–286. doi:10.1097/MED.0000000000000074.

2.      Narisa Futrakul, Ankanee Chanakul, Prasit Futrakul & Tawatchai Deekajorndech (2015) Early stage of vascular disease and diabetic kidney disease: an underrecognized entity, Renal Failure, 37:8, 1243-1246, DOI: 10.3109/0886022X.2015.1073054

3.      Liviu Segall, Ionut Nistor, and Adrian Covic, “Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review,” BioMed Research International, vol. 2014, Article ID 937398, 21 pages, 2014. https://doi.org/10.1155/2014/937398.

4.      Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020

5.      Wang H et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388(10053):1459–544.

6.      World Health Organization. (2019). World Heart Day. [online] Available at: https://www.who.int/cardiovascular_diseases/world-heart-day/en/ [Accessed 31 Jul. 2019].

7.      Arnold SV et al. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab 2018; 20(8):2000–3.

8.      Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. J Cardiol 2011; 57(1):8–17.

9.      ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal (2013) 34, 3035–3087 doi:10.1093/eurheartj/eht108

10.   JernBerg T et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015; 36:1163-1170.

11.   National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Disease Statistics for the United States: December 2016. National Institutes of Health [cited 2018 Aug 28]. Available from: URL: https://www.niddk.nih.gov/health-资讯rmation/health-statistics/kidney-disease.

12.   AstraZeneca data on file. Programme screening and treatment & Total programme KPIs. June 2019.

13.   R.L. Sacco et al. The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths from Cardiovascular Diseases and Stroke. Circulation 2016; 133:e674-e690. Available at:  https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000395 Last accessed July 2019.

 


Veeva ID: Z4-23524

Date of next review: July 2021